109 related articles for article (PubMed ID: 2785434)
1. Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo.
Wright JE; Dreyfuss A; el-Magharbel I; Trites D; Jones SM; Holden SA; Rosowsky A; Frei E
Cancer Res; 1989 May; 49(10):2592-6. PubMed ID: 2785434
[TBL] [Abstract][Full Text] [Related]
2. Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
Houghton JA; Williams LG; Cheshire PJ; Wainer IW; Jadaud P; Houghton PJ
Cancer Res; 1990 Jul; 50(13):3940-6. PubMed ID: 2354443
[TBL] [Abstract][Full Text] [Related]
3. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.
Houghton JA; Maroda SJ; Phillips JO; Houghton PJ
Cancer Res; 1981 Jan; 41(1):144-9. PubMed ID: 7448754
[TBL] [Abstract][Full Text] [Related]
4. Effect of sequence of administration of methotrexate, leucovorin, and 5-fluorouracil on mammary tumor growth and survival in syngeneic C3H mice.
Heppner GH; Calabresi P
Cancer Res; 1977 Dec; 37(12):4580-3. PubMed ID: 303542
[TBL] [Abstract][Full Text] [Related]
5. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
6. Leucovorin and folic acid regimens for selective expansion of murine 5,10-methylenetetrahydrofolate pools.
Wright JE; Pardo M; Sayeed-Shah U; Alperin W; Rosowsky A
Biochem Pharmacol; 1995 Mar; 49(5):677-85. PubMed ID: 7534077
[TBL] [Abstract][Full Text] [Related]
7. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil.
Berger SH; Hakala MT
Mol Pharmacol; 1984 Mar; 25(2):303-9. PubMed ID: 6608049
[TBL] [Abstract][Full Text] [Related]
8. [Comparison between leucovorin and cisplatin as a modulator of 5-fluorouracil].
Iba T; Yagi Y; Kidokoro A; Fukunaga T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):479-83. PubMed ID: 8452385
[TBL] [Abstract][Full Text] [Related]
9. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
[TBL] [Abstract][Full Text] [Related]
10. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263
[TBL] [Abstract][Full Text] [Related]
11. Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts.
Houghton JA; Williams LG; de Graaf SS; Cheshire PJ; Rodman JH; Maneval DC; Wainer IW; Jadaud P; Houghton PJ
Cancer Res; 1990 Jun; 50(12):3493-502. PubMed ID: 2140289
[TBL] [Abstract][Full Text] [Related]
12. In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma.
Nadal JC; Van Groeningen CJ; Pinedo HM; Peters GJ
Biomed Pharmacother; 1988; 42(6):387-93. PubMed ID: 3064823
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms.
Zhang ZG; Rustum YM
Semin Oncol; 1992 Apr; 19(2 Suppl 4):46-50. PubMed ID: 1532459
[TBL] [Abstract][Full Text] [Related]
14. Modulation of 5-fluorouracil in mice using uridine diphosphoglucose.
Codacci-Pisanelli G; Kralovanszky J; van der Wilt CL; Noordhuis P; Colofiore JR; Martin DS; Franchi F; Peters GJ
Clin Cancer Res; 1997 Feb; 3(2):309-15. PubMed ID: 9815688
[TBL] [Abstract][Full Text] [Related]
15. Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies.
Farrugia DC; Aherne GW; Brunton L; Clarke SJ; Jackman AL
Clin Cancer Res; 2000 Sep; 6(9):3646-56. PubMed ID: 10999757
[TBL] [Abstract][Full Text] [Related]
16. Leucovorin modulation of fluorouracil.
Grogan L; Sotos GA; Allegra CJ
Oncology (Williston Park); 1993 Aug; 7(8):63-72; discussion 75-6. PubMed ID: 8398636
[TBL] [Abstract][Full Text] [Related]
17. Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas.
Van Laar JA; Rustum YM; Van der Wilt CL; Smid K; Kuiper CM; Pinedo HM; Peters GJ
Cancer Chemother Pharmacol; 1996; 39(1-2):79-89. PubMed ID: 8995503
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Spears CP; Gustavsson BG; Berne M; Frösing R; Bernstein L; Hayes AA
Cancer Res; 1988 Oct; 48(20):5894-900. PubMed ID: 3167844
[TBL] [Abstract][Full Text] [Related]
19. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
20. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
Spears CP; Shahinian AH; Moran RG; Heidelberger C; Corbett TH
Cancer Res; 1982 Feb; 42(2):450-6. PubMed ID: 6173112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
